Gotistobart Nearly Doubled Median OS versus SOC Chemo in Previously Treated Squamous NSCLC Patients September 16, 2026
Ratio Therapeutics Enters into Research Collaboration and License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program September 16, 2026
Zipalertinib + chemo Demonstrates 6-Month Median PFS Benefit in REZILIENT3 Ph 3 Trial in 1L EGFR Exon 20 Insertion Mutation NSCLC September 16, 2026
FDA clears IND application to initiate Ph 1 study for PRT13722 for HR+/HER2- breast cancer patients September 16, 2026
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda in FAP-α Positive Solid Tumors September 16, 2026
First Patient dosed in Ph 1 Trial of CBX-663 for Treatment of Multiple Hematologic and Solid Malignancies September 16, 2026
FAILED TRIAL: SERENA-4 trial of Etcamah + palbociclib did not meet primary objective of statistically significant PFS improvement September 16, 2026
FDA “Study May Proceed” Notice and IND Clearance Received for the Evaluation of TBS-2025 in Molecularly Defined Subsets of AML and Other Blood-Related Cancers September 16, 2026
Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy September 16, 2026
First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology September 16, 2026
US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit with HCB101 September 16, 2026
Complete Full Cohort Ph 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent NSCLC Announced September 16, 2026
Results from Ph 3 Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO September 16, 2026
Positive results announced from registrational Ph 1/2 ARROS-1 trial of Jideytro (zidesamtinib) in patients with advanced or metastatic TKI-naive ROS1-positive NSCLC September 16, 2026
Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed SCLC in China September 16, 2026
RYBREVANT® (amivantamab-vmjw) + chemo delivers long median OS in EGFR exon 20 insertion mutation-positive NSCLC September 16, 2026
Ph 3 data for Tam-Peli shows significantly improved OS in Chinese patient population with relapsed SCLC September 16, 2026
Tagrisso demonstrated eight-year survival in early-stage EGFR-mutated lung cancer in ADAURA Ph 3 trial September 16, 2026
Enhertu demonstrated a median PFS of 14.3 months IN 1L HER2-mutant advanced NSCLC in DESTINY-Lung04 Ph 3 trial September 16, 2026
US FDA IND Clearance and Australian Regulatory Clearance granted for [²²⁵Ac]Ac-FL-261 Ph 1 Clinical Trial September 16, 2026
FDA IND clearance to initiate a first-in-human Ph 1 trial of lead peptide-drug conjugate program TS-104 September 16, 2026
